Lund, Sweden — 29 April 2026 — Camurus (CAMX) today announces that the Annual Report for 2025 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).
In 2025, Camurus achieved substantial growth of revenue and profitability, while enhancing patient access to effective treatments, expanding the commercial presence, and progressing a pipeline positioned to drive long-term growth.
The Annual Report also includes Camurus’ sustainability report.
For more information
Fredrik Tiberg, President & CEO
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 10:00 am CET on 29 April 2026.